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Endovascular Intervention in Patients with Critical Limb Ischemia in Taiwan:
Patient Outcomes in 333 Consecutive Limb Procedures with a 6-year Follow-up
Hsuan Li Huang1
1Buddhist Tzu-Chi General Hospital, Taipei branch, New Taipei City, Taiwan,
Republic of China
Background: The long-term outcomes for endovascular intervention (EVI) in Asian
people with critical limb ischemia (CLI) are still uncertain. This study was designed to
assess the feasibility and patient outcomes after EVI for Taiwanese patients with CLI.
Methods: From June 2005 to December 2011, 270 patients underwent EVI for CLI of
333 limbs. Primary patency (PP), assisted primary patency (AP), limb salvage, sustained
clinical success (SCS), secondary sustained clinical success (SSCS) and survival were
assessed using Kaplan-Meier analysis.
Results: The procedural success rate was 94% and 53% of legs required stent
implantation to optimize the procedural result. The periprocedural mortality and major
complications rate within 30 days was 0.6% and 6.9%, respectively. During the mean
follow-up time of 2720 months (1-77), 64 patients died and 25 legs underwent major
amputation with a total of 93% follow-up rate. 81% of patients with tissue loss had wound
healing at 6 months and 75% of patients can be ambulatory with or without assist device
at 1 year. Overall survival rate of CLI patients at 1, 3, 5 year was 88%, 70% and 61%. The
rates of free from major and any amputation at 1 year were 90% and 78%, respectively
and can be maintained to 5 years. The PP and AP at 1, 3, 5 year was 58%, 37%, 31% and
79%, 61% and 52%, respectively. The SCS and SSCS were 65%, 46%, 38% and 80%,
64%, 55% at 1, 3,5 years, respectively.
Conclusions: EVI proved to be a safe and feasible procedure for CLI patients. Sustained
limb salvage and clinical success can be achieved with an active surveillance program and
prompt assisted intervention during long-term follow-up.
TCT-152
Impact of Body Surface Area on Outcomes in Patients With Lower Extremity
Peripheral Arterial Disease
Alix Tercius1, Tonga Nfor2, Naoyo Mori3, Fuad Jan2, Alexander Mayer2,
Khawaja Ammar2, Anjan Gupta2, Suhail Allaqaband2, Tanvir Bajwa2
1Ohio State University, Columbus, OH, 2ACS, Aurora Sinai/St. Luke’s Med Ctrs,
Univ Wisconsin School of Medicine and Public Health, Milwaukee, WI, 3Center
for Urban Population Health, University of Wisconsin-Milwaukee, Milwaukee, WI
Background: Body surface area (BSA) is a good indicator of overall metabolic mass.
We investigated whether BSA affects clinical outcome in patients with lower extremity
peripheral arterial disease (LEPAD).
Methods: We reviewed records for 365 patients with new diagnosis of LEPAD from
2001 to 2007. Patients were followed for a mean of 62  43 months. Patients with
stenosis of 70% or more were included. Each diseased leg was considered 1 case for a
total of 602 cases. We calculated BSA in meters squared using Mosteller formula. Based
on BSA, cases were divided into three groups: low (1.2BSA1.72), normal
(1.72BSA2) and high (2BSA3). Primary endpoint was time to all-cause mortality;
secondary endpoints were time to amputation and time to revascularization.
Results: Increased BSA demonstrated an inverse linear relationship with mortality
(Graph), even after adjusting for age, body mass index, sex, diabetes, hypertension,
coronary artery disease and medications. Stratified analysis confirmed this effect (Table).
High BSA was also associated with a longer time-to-amputation rate in contrast to normal
and low BSA (hazard ratio 0.54, 95% confidence interval 0.24-1.18, p0.012).
Conclusions: High BSA reduces risk of all-cause mortality and lengthens time to
amputation in patients with lower extremity peripheral arterial disease.
Subgroup All-Cause Mortality Analysis by Multivariate Cox Regression
Subgroup
BSA:
1.2–1.72
(n109)
BSA: 1.72–2
(n129)
BSA: 2–3
(n127)
BMI  30 Mortality (n) 36 30 8
HR (95% CI) 0.60 (0.29–1.24) 0.17 (0.06–0.52)
P value 0.17 0.002
BMI  30 Mortality (n) 3 6 14
HR (95% CI) 1.08 (0.01–11.4) 2.8 (0.00–18.20)
P value 0.98 0.60
Female Mortality (n) 24 15 4
HR (95% CI) 0.78 (0.21–2.85) 0.18 (0.03–1.27)
P value 0.71 0.08
Male Mortality (n) 15 21 18
HR (95% CI) 0.62 (0.23–1.67) 0.28 (0.08–0.90)
P value 0.34 0.03
Age  75 Mortality (n) 20 19 17
HR (95% CI) 0.35 (0.15–0.82) 0.19 (0.06–0.54)
P value 0.016 0.002
Age  75 Mortality (n) 19 17 5
HR (95% CI) 2.69 (0.71–10.23) 0.43 (0.08–2.35)
P value 0.14 0.33
Suprainguinal Mortality (n) 8 2 0
HR (95% CI) 1.10 (0.00–40.6) 0 (0–10.4)
P value 0.078 0.99
Infrainguinal Mortality (n) 26 27 14
HR (95% CI) 0.77 (0.34–1.74) 0.17 (0.06–0.47)
P value 0.54 0.001
Hazard ratio when compared to the subgroup BSA 1.2-1.72, according to the
Mosteller formula.
BMI, body mass index; BSA, body surface area; CI, confidence interval; HR,
hazard ratio.
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Renal Artery Aneurysms. First Human Treatment With The Multilayer Flow
Modulator
Michel Henry1, Amira Benjelloun2, Isabelle Henry3, Antonios Polydorou4
1Cabinet de cardiologie, nancy, France, 2Clinique Coeur et Vaisseaux, Rabat,
Morocco, 3Polyclinique Bois Bernard, Bois bernard, France, 4Panteleimon
General Hospital, Athens, Greece
Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to high
risk, endovascular procedures have been proposed (coils, graft...). All these techniques
have some drawbacks, potential complications and contraindications. We propose a new
technique: the Multilayer Flow Modulator (MFM*), a self expandable stent and we report
8 cases.
Methods: This MFM* is a 3D braided tube made of several interconnected layers
without any covering. Our earliest tests, in vitro (theorical simulation computerized Fluid
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com
B44 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Peripheral Vascular Disease and Intervention
P
O
ST
E
R
S
dynamics, Molecular Modelization) & in vivo. demonstrate that this MFM reduces the
velocity in the aneurismal sac up to 90% by modifying the hemodynamic conditions. A
saccular aneurysm without collateral branch will thrombose quickly. If a collateral branch
is present the flow is directed towards this branch leading to shrinkage of the aneurysm.
In fusiform aneurysms the flow is laminated, the vortexes eliminated, eliminating the risk
of rupture. Animal experiments show excellent results. Moreover, as demonstrated in
animal and human studies this MFM preserves the collateral branches and increases the
flow in them, allowing the possibility to cover any artery without compromising the flow.
Results: 8 RAAs (right: 5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM*
6 pts had atheromatous disease, 2 a fibromuscular dysplasia. One pt had a solitary kidney.
All these pts had hypertension, 2 a severe coronary disease. 10 MFM(A: 5 to 6 mm, length
30 to 60 mm) loaded in a 6 F sheath implanted by femoral approach through 8 F guiding
catheter. These stents covered major renal branches without compromising the flow.
Technical success: 100%. No complications. Immediately it appears an important
reduction of the velocities inside the aneurismal sac. 6 to 36 month follow up will be
presented. All aneurysms thrombosed with diameter reduction in some pts. The throm-
bosis could take several weeks depending on the importance of collateral branches. All the
side branches remain patent.
Conclusions: The MFM* is a new technique which seems to be promising to treat renal
aneurysms. Collateral branches can be covered without compromising the flow and risk
of renal infarction. Larger study is ongoing.
TCT-154
The Multilayer Flow Modulator Stent For The Treatment Of Popliteal
Aneurysm
Michel Henry1, Amira Benjelloun2, Isabelle Henry3, Antonios Polydorou4
1Cabinet de cardiologie, nancy, France, 2Clinique Coeur et Vaisseaux, RABAT,
Morocco, 3Polyclinique Bois Bernard, BOIS BERNARD, France, 4Panteleimon
General Hospital, Athens, Greece
Background: Popliteal Artery Aneurysms (PA) are traditionally treated surgically.
Endovascular procedures with implantation of stent grafts or covered stents have been
proposed as an alternative to surgery. Results are encouraging but some problems remain
(aneurysm rupture, endoleaks, collateral branch thrombosis. . .). We developed a new
concept of stent, the Multilayer Flow Modulator (MFM) to treat aneurysms and try to
avoid some drawbacks encountered with endografts.
Methods: This MFM is a 3 Dimensional braided tube made of several interconnected layers
without any covering. Our earliest tests in vitro (theorical simulation, computerized Fluid
dynamics, Molecular Modelization) and in vivo demonstrate that this MFM reduces the
velocity in the aneurismal sac up to 90% by modifying the hemodynamic conditions. A
saccular aneurysm without collateral branch will thrombose quickly. If a collateral branch is
present the flow is directed towards this branch leading to shrinkage of the aneurysm. Animal
experiments show excellent results. Moreover, as demonstrated in animal and human studies
this MFM preserves the collateral branches allowing the possibility to cover any artery without
compromising the flow (renal, digestive arteries, supra aortic vessels . . .).
Results: 5 PA were treated with the MFM (male: 5, mean age: 65 y.) 9 stents (Ø6 to 8 mm,
length 40 to 120 mm) were implanted by percutaneous ipsilateral femoral approach through 8F
sheath. Technical success in all patients. All aneurysm thrombosed. Mid-term follow up will
be presented. No stent fracture. This MFM seems well indicated for this popliteal location.
Conclusions: A new concept of stent, the MFM is developed to treat aneurysm. It opens
a new approach to treat peripheral aneurysms avoiding most of the complications
encountered with current endovascular techniques. The results obtained seem promising.
A larger study is ongoing.
TCT-155
A New Concept Of Stent: The Multilayer Flow Modulator. First Human
Study In Peripheral And Visceral Aneurysms
Michel Henry1, Amira Benjelloun2, Isabelle Henry3, Antonios Polydorou4
1Cabinet de cardiologie, nancy, France, 2Clinique Coeur et Vaisseaux, RABAT,
Morocco, 3Polyclinique Bois Bernard, BOIS BERNARD, France, 4Panteleimon
General Hospital, Athens, Greece
Background: Arterial aneurysms (An) are traditionally treated surgically, but more and more
by interventional procedures with a high technical success rate, but some problems are not
solved like protection of aneurysm rupture, endoleaks, stent thrombosis, collateral branch
thrombosis. We developed a new concept of stent, the Multilayer Flow Modulator (MFM*) to
treat An. and try to avoid some drawbacks encountered with endografts.
Methods: This MFM* is a 3 Dimensional braided tube made of several interconnected
layers without any covering. Our earliest in vitro (theorical simulation), computerized
Fluid dynamics, Molecular Modelization and in vivo tests demonstrated that this MFM*
reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic
conditions. A saccular aneurysm without collateral branch will thrombose quickly. If a
collateral branch is present the flow is directed towards this branch leading to shrinkage
of the aneurysm. Animal experiments show excellent results. Moreover, as demonstrated
in animal and human studies this MFM preserves the collateral branches allowing the
possibility to cover any artery without compromising the flow (renal, digestive arteries,
supra aortic vessels. . .).
Results: 39 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8, mesenteric:1,
Subclavian : 1) were treated with the MFM* (male:30, mean age 62	/8 y) (51 stents
A 5 to 14 mm; length 40 to 120 mm) were implanted to treat these aneurysms, by femoral
approach (38 cases), brachial approach (1 case), Technical success in all patients. No
complications. All An. thrombosed with diameter reduction in some pts. The thrombosis
could take several weeks depending on the importance of collateral branches. 6 month to
36 month follow up will be presented and we will discuss the time needed to achieve
exclusion of the An. All the side branches remained patent.
Conclusions: A new concept of stent, the MFM* (without any covering) is developed to
treat An. It opens a new approach to treat peripheral An. avoiding most of the
complications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
TCT-156
Renal Angioplasty And Stenting. Limitations. Role Of Embolic Protection
Devices
Isabelle Henry1, Amira Benjelloun2, Michel Henry3
1Polyclinique Bois Bernard, BOIS BERNARD, France, 2Clinique Coeur et
Vaisseaux, RABAT, Morocco, 3Cabinet de cardiologie, nancy, France
Background: Despite good immediate and long-term results, post procedural deteriora-
tion of the renal function (RF) may occur after Renal Artery Angioplasty and Stenting
(RAAS) in 20-40% of the patients, which limits the immediate benefits of the technique.
Atheroembolism seems to play an important role. We evaluate feasibility and safety of
RAAS utilizing a distal protection device (DPD) to reduce the risk of atheroembolism and
avoid deteriorations of the RF.
Methods: 161 RAAS performed under DPD in 141 hypertensive patients (M:97). Mean age:
64.9  11.8 yrs with atherosclerotic renal artery stenosis (20 bilateral). 11 pts had solitary
kidneys, 57 renal insufficiencies. We used occlusion balloon (n  46) or filters
(n  115). We recently experimented and treated 12 patients with a new filter the Fibernet
(Lumen Biomedical Plymouth MN) which can capture particles of 40without compromising
the flow. Generated debris removed and analyzed. Blood pressure and serum creatinine levels
followed. Techniques of RAAS under protection, limitations will be discussed.
Results: Immediate technical success: 100%. Visible debris aspirated with Percusurge
from all patients. Mean particle number: 98.1  60.00. Mean diameter: 201.2  76
(38-6206). With current filters debris were removed in 80% of the cases. With the Fibernet
visible debris were removed in all cases. Mean debris surface area: 121mm2. Mean
number of particles 28-60 : 2136  776, 60. We observed one acute RF
deterioration. Mean follow-up: 31.2 16 months. Mean creatinine level remains constant
during follow-up. At 6 months (121 patients) 89 patients stabilized, 31 with baseline renal
insufficiency improved and we had only one RF deterioration (1%) in a patient with
moderate renal insufficiency. At 2 years (97 patients) 69 stabilized, 24 improved and we
only had 4 RF deterioration (5%).
Conclusions: This study demonstrates the feasibility and safety of DPD during renal
interventions to protect against atheroembolism and seems to avoid RF deterioration after
the procedure and in the long-term. Indications will be discussed. Improvements in DPD
for renal stenting are mandatory. Randomized studies are awaited.
TCT-157
Increased Local Cytokine Production at Culprit Superficial Femoral Artery
Plaques
Cameron Donaldson1, David Schneider1, Daniel Bertges2, Julie Adams2,
Nader Elgharib1, Ellie Mueller1, William Prabhu1, Taka Ashikaga3,
Amy Henderson1, Harold Dauerman1
1University of Vermont, Division of Cardiology, Burlington, VT, 2University of
Vermont, Division of Vascular Surgery, Burlington, VT, 3University of Vermont,
Department of Medical Biostatistics, Burlington, VT
Background: Characterization of arterial cytokines taken directly from areas of culprit
superficial femoral artery (SFA) stenosis has not been studied. We hypothesized that
arterial cytokine concentrations would be greater at sites of culprit stenosis, implicating
inflammatory mediators in progression of SFA disease.
Methods: Twenty patients with 50% angiographic stenosis of the SFA had blood drawn
just proximal to the lesion and from a contralateral site free of significant disease. A microplate
immunoassay was used to determine the concentrations of 42 distinct cytokines and growth
factors. Univariate analysis was used to compare blood collected at the two sites. Interaction
terms identified clinical factors potentially impacting cytokine concentrations.
Results: The concentrations of soluble CD40 ligand (CD40L; mean 212 and 177 pg/ml,
p0.01) and tumor necrosis factor beta (TNF-B; mean 16.6 and 15.9 pg/ml, p0.03) were
increased in areas of stenosis (Figure). Predictors of greater concentrations at sites of stenosis
were bilateral ankle-brachial index 0.90 (p0.04), claudication (p0.03), no known
peripheral arterial disease or non-healing ulcer (p0.05), low leukocyte count (p0.03) and
Rutherford class (p0.05), as well as lack of aspirin, clopidogrel or statin (p0.05).
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